Background The effect of weight loss on different plasma lipid subclasses at the molecular level is unknown. The aim of this study was to examine whether a diet-induced weight reduction result in changes in the extended plasma lipid profiles (lipidome) in subjects with features of metabolic syndrome in a 33-week intervention. Methodology/Principal Findings Plasma samples of 9 subjects in the weight reduction group and 10 subjects in the control group were analyzed using mass spectrometry based lipidomic and fatty acid analyses. Body weight decreased in the weight reduction group by 7.8±2.9% (p<0.01). Most of the serum triacylglycerols and phosphatidylcholines were reduced. The decrease in triacylglycerols affected predominantly the saturated short chain fatty acids. This decrease of saturated short chain fatty acid containing triacylglycerols correlated with the increase of insulin sensitivity. However, levels of several longer chain fatty acids, including arachidonic and docosahexanoic acid, were not affected by weight loss. Levels of other lipids known to be associated with obesity such as sphingolipids and lysophosphatidylcholines were not altered by weight reduction. Conclusions/Significance Diet-induced weight loss caused significant changes in global lipid profiles in subjects with abnormal glucose metabolism. The observed changes may affect insulin sensitivity and glucose metabolism in these subjects. Trial Registration ClinicalTrials.gov NCT00621205
References
[1]
Moller DE, Kaufman KD (2005) Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56: 45–62.
[2]
Yu-Poth S, Zhao G, T E, Naglak M, Jonnalagadda S, et al. (1999) Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 69: 632–646.
[3]
Stefanick ML, Mackey S, Sheehan M, Ellswotrh N, Haskell WL, et al. (1998) Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 339: 12–20.
[4]
Metz JA, Stern JS, Kris-Etherton P, Reusser ME, Morris CD, et al. (2000) A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 160: 2150–2158.
[5]
Lelliott C, Vidal-Puig AJ (2005) Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes relat Metab Disord 28: Suppl. 4S22–S28.
[6]
Unger R (2002) Lipotoxic diseases. Annu Rev Med 53: 319–336.
[7]
Medina-Gomez G, Gray S, Yetukuri L, Shimomura K, Campbell M, et al. (2007) PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 3: e64.
[8]
Storlien LH, Baur LA, Kriketos AD, Pan DA, Cooney GJ, et al. (1996) Dietary fats and insulin action. Diabetologija 39: 621–631.
[9]
Vessby B (2003) Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 14: 15–19.
[10]
Laaksonen DE, Lakka TA, Lakka H-M, Nyyssonen K, Rissanen T, et al. (2002) Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med 19: 456–464.
[11]
Warensj？ E, Riserus U, Vessby B (2005) Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 48: 1999–2005.
[12]
Vessby B, Aro A, Skarfors E, Berglund L, Salminen I, et al. (1994) The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes 43: 1353–1357.
[13]
Laitinen JH, Ahola IE, Sarkkinen ES, Winberg RL, Harmaakorpi-Iivonen PA, et al. (1993) Impact of intensified dietary therapy on energy and nutrient intakes and fatty acid composition of serum lipids in patients with recently diagnosed non-insulin-dependent diabetes mellitus. J Am Diet Assoc 93: 276–283.
[14]
Nelson JC, Jiang X-C, Tabas I, Tall A, Shea S (2006) Plasma sphingomyelin and subclinical atherosclerosis: Findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 163: 903–912.
[15]
Samad F, Hester KD, Yang G, Hannun YA, Bielawski J (2006) Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55: 2579–2587.
[16]
Mehta D (2005) Lysophosphatidylcholine: an enigmatic lysolipid. Am J Physiol Lung Cell Mol Physiol 289: L174–175.
[17]
Rabini R, Galassi R, Fumelli P, Dousset N, Solera M, et al. (1994) Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes 43: 915–919.
[18]
Lusis AJ (2000) Atherosclerosis. Nature 407: 233–241.
[19]
Pietil？inen KH, Sysi-Aho M, Rissanen A, Sepp？nen-Laakso T, Yki-J？rvinen H, et al. (2007) Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects - a monozygotic twin study. PLoS ONE 2: e218.
[20]
Watson AD (2006) Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res 47: 2101–2111.
[21]
Yetukuri L, Katajamaa M, Medina-Gomez G, Sepp？nen-Laakso T, Puig AV, et al. (2007) Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 1: e12.
[22]
Ekroos K, Chernushevich IV, Simons K, Shevchenko A (2002) Quantitative profiling of phospholipids by multiple precursor ion scanning on a hybrid quadrupole time-of-flight mass spectrometer. Anal Chem 74: 941–949.
[23]
Han X, Gross RW (2003) Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J Lipid Res 44: 1071–1079.
[24]
Schwudke D, Oegema J, Burton L, Entchev E, Hannich JT, et al. (2006) Lipid profiling by multiple precursor and neutral loss scanning driven by the data-dependent acquisition. Anal Chem 78: 585–595.
[25]
McAnoy AM, Wu CC, Murphy RC (2005) Direct qualitative analysis of triacylglycerols by electrospray mass spectrometry using a linear ion trap. J Am Soc Mass Spectrom 16: 1498–1509.
[26]
Hermansson M, Uphoff A, Kakela R, Somerharju P (2005) Automated quantitative analysis of complex lipidomes by liquid chromatography/mass spectrometry. Anal Chem 77: 2166–2175.
[27]
Houjou T, Yamatani K, Imagawa M, Shimizu T, Taguchi R (2005) A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry. Rapid Comm Mass Spectrom 19: 654–666.
[28]
Kolehmainen M, Salopuro T, Schwab US, Kekalainen J, Kallio P, et al. (2007) Weight reduction modulates expression of genes involved in extracellular matrix and cell death: the GENOBIN study. Int J Obes. doi: 10.1038/sj.ijo.0803718.
[29]
Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 285: 2486–2497.
[30]
Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, et al. (2000) AHA Dietary Guidelines : Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102: 2284–2299.
[31]
Sarkkinen E, Schwab U, Niskanen L, Hannuksela M, Savolainen M, et al. (1996) The effects of monounsaturated-fat enriched diet and polyunsaturated-fat enriched diet on lipid and glucose metabolism in subjects with impaired glucose tolerance. Eur J Clin Nutr 50: 592–598.
[32]
Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, et al. (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5: 1003–1015.
[33]
Sepp？nen-Laakso T, Laakso I, Hiltunen R (2002) Analysis of fatty acids by gas chromatography, and its relevance to research on health and nutrition. Anal Chim Acta 465: 39–62.
[34]
Laaksonen R, Katajamaa M, P？iv？ H, Sysi-Aho M, Saarinen L, et al. (2006) A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin induced changes in muscle. PLoS ONE 1: e97.
[35]
Medina-Gomez G, Virtue S, Lelliott C, Boiani R, Campbell M, et al. (2005) The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific Peroxisome Proliferator-Activated Receptor-{gamma}2 isoform. Diabetes 54: 1706–1716.
[36]
Katajamaa M, Miettinen J, Oresic M (2006) MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics 22: 634–636.
[37]
Storey JD (2002) A direct approach to false discovery rates. J R Stat Soc B 64: 479–498.
[38]
Willett WC (1998) Nutritional epidemiology. New York, NY, USA: Oxford University Press.
[39]
Tremblay AJ, Despres J-P, Piche M-E, Nadeau A, Bergeron J, et al. (2004) Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome. Metabolism 53: 310–317.
[40]
Vessby B, Tengblad S, Lithell H (1994) Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia 37: 1044–1050.
[41]
Summers LKM, Fielding BA, Bradshaw HA, Ilic V, Beysen C, et al. (2002) Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia 45: 369–377.
[42]
Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, et al. (2001) Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU study. Diabetologia 44: 312–319.
[43]
Shimabukuro M, Zhou Y, Levi M, Unger R (1998) Fatty acid induced beta-cell apoptosis: a link between diabetes and obesity. Proc Natl Acad Sci USA 95: 2498–2502.
[44]
Wei Y, Wang D, Topczewski F, Pagliassotti MJ (2006) Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 291: E275–281.
[45]
Sweeney G, Nazir D, Clarke C, Goettsche G (1996) Ethanolamine and choline phospholipids in nascent very-low-density lipoprotein particles. Clin Invest Med 19: 243–250.
[46]
？gren JJ, Hallikainen M, Vidgren H, Miettinen TA, Gylling H (2006) Postprandial lipemic response and lipoprotein composition in subjects with low or high cholesterol absorption efficiency. Clin Chim Acta 366: 309–315.
[47]
Yang LV, Radu CG, Wang L, Riedinger M, Witte ON (2005) Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 105: 1127–1134.
[48]
Shalina S, Ousman SD (2000) Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 30: 92–104.
Murugesan G, Fox PL (1996) Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized Low Density Lipoprotein. J Clin Invest 97: 2736–2744.
[51]
Schmidt K, Klatt P, Graier WF, Kostner GM, Kukovetz WR (1992) High-density lipoprotein antagonizes the inhibitory effects of oxidized low-density lipoprotein and lysolecithin on soluble guanylyl cyclase. Biochem Biophys Res Comm 182: 302–308.
[52]
Matsuda Y, Hirata K, Inoue N, Suematsu M, Kawashima S, et al. (1993) High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 72: 1103–1109.
